Zevra Therapeutics, Inc. $ZVRA Stock: Profund Advisors LLC Grows Holdings

Profund Advisors LLC raised its position in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 605.6% in the third quarter, HoldingsChannel.com reports. The firm owned 109,547 shares of the company’s stock after buying an additional 94,021 shares during the period. Profund Advisors LLC’s holdings in Zevra Therapeutics were worth $1,202,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the company. State of Wyoming bought a new stake in shares of Zevra Therapeutics in the 3rd quarter worth $81,000. China Universal Asset Management Co. Ltd. grew its holdings in Zevra Therapeutics by 15.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,835 shares of the company’s stock worth $123,000 after acquiring an additional 1,427 shares during the period. Sterling Capital Management LLC lifted its holdings in Zevra Therapeutics by 2,396.6% in the 3rd quarter. Sterling Capital Management LLC now owns 21,895 shares of the company’s stock valued at $240,000 after acquiring an additional 21,018 shares during the last quarter. Inspire Investing LLC boosted its position in shares of Zevra Therapeutics by 21.5% during the 3rd quarter. Inspire Investing LLC now owns 210,219 shares of the company’s stock valued at $2,306,000 after purchasing an additional 37,203 shares in the last quarter. Finally, Mystic Asset Management Inc. boosted its position in shares of Zevra Therapeutics by 0.9% during the 3rd quarter. Mystic Asset Management Inc. now owns 355,380 shares of the company’s stock valued at $3,899,000 after purchasing an additional 3,270 shares in the last quarter. 35.03% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on ZVRA shares. William Blair raised shares of Zevra Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 23rd. Guggenheim reduced their target price on shares of Zevra Therapeutics from $24.00 to $23.00 and set a “buy” rating for the company in a report on Friday, August 7th. HC Wainwright restated a “buy” rating and set a $26.00 target price on shares of Zevra Therapeutics in a report on Thursday, August 20th. Wall Street Zen raised Zevra Therapeutics from a “hold” rating to a “buy” rating in a report on Sunday, July 12th. Finally, Canaccord Genuity Group cut their price objective on Zevra Therapeutics from $29.00 to $20.00 and set a “buy” rating for the company in a research report on Monday, July 27th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $27.14.

Zevra Therapeutics Trading Down 1.8%

Shares of ZVRA stock opened at $10.10 on Tuesday. Zevra Therapeutics, Inc. has a 1-year low of $8.01 and a 1-year high of $15.03. The company has a market capitalization of $599.78 million, a price-to-earnings ratio of 10.98 and a beta of 0.98. The stock’s fifty day simple moving average is $11.14 and its 200-day simple moving average is $10.74.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $0.25 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.14. The firm had revenue of $39.66 million for the quarter, compared to analyst estimates of $33.88 million. Zevra Therapeutics had a return on equity of 54.54% and a net margin of 42.82%. On average, sell-side analysts predict that Zevra Therapeutics, Inc. will post 0.72 EPS for the current year.

Insider Activity

In other news, CEO Neil F. Mcfarlane sold 20,000 shares of the company’s stock in a transaction dated Monday, October 12th. The stock was sold at an average price of $11.25, for a total value of $225,000.00. Following the transaction, the chief executive officer owned 417,225 shares in the company, valued at $4,693,781.25. This represents a 4.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Corey Watton sold 12,300 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $11.25, for a total transaction of $138,375.00. Following the completion of the sale, the director directly owned 1,800 shares of the company’s stock, valued at $20,250. This trade represents a 87.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 3.70% of the company’s stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with significant unmet medical needs. The company combines traditional drug development with data science and patient-focused research to advance therapies for diseases that may have limited treatment options.

Zevra’s lead commercial product is MIPLYFFA (arimoclomol), which is approved in the United States for the treatment of neurological manifestations of Niemann-Pick disease type C in adults and children aged 2 years and older, in combination with miglustat.